Zepbound™ (tirzepatide) Approved for Chronic Weight Management

Posted: Nov 08 in Weight Loss Medication by

The most effective medication ever seen for weight loss was approved by the FDA this morning.

Zepbound™ contains the same active ingredient as Mounjaro™ (tirzepatide). Much like Novo Nordisk markets semaglutide as Ozempic™ and Rybelsus™ for diabetes, and Wegovy™ for chronic weight management, Zepbound™ is identical to Mounjaro™, but is indicated for medical weight loss.

In clinical studies, patients treated with Zepbound lost 20-22% of their body weight at the higher doses, or an average of 50 pounds. This is even more weight loss than the 15-16% which was seen in the Wegovy studies for medical weight loss.

The medication is recommended to be used in addition to a properly structured eating plan along with proper physical activity.

Keep in mind that Zepbound is not available for purchase, yet – Elli Lilly has announced it will be available after Thanksgiving, 2023. If you are interested in this treatment, now is a great time to check with your insurance company to see if you have coverage for anti-obesity medications like Wegovy and Zepbound.

We will not initiate Zepbound with a voicemail or portal message – if you are interested in starting Zepbound, please schedule a visit with Dr. Lazarus, Heather or Jamie after Thanksgiving.

Please remember that there are many places advertising “compounded tirzepatide.” We do not advise purchasing this version, as we do not know what the source is. Both the FDA and the Obesity Medicine Association have issued warnings about compounding tirzepatide and semaglutide regarding potential safety concerns.

Read the FDA announcement about the approval of Zepbound for chronic weight management here.

Leave Comment